Novanta Inc. — FY 2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. This is an annual report, not a standalone Q4 filing; selected quarterly data are included. All amounts are U.S. dollars unless noted.
Business context
Novanta supplies precision technology components and subsystems to medical and advanced industrial OEMs. Its three reporting segments are Photonics, Vision, and Precision Motion. Each end market represented approximately 50% of FY 2018 revenue. No customer contributed more than 10% of annual revenue.
Financial performance
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $614.3 million | $521.3 million |
| Gross profit / margin | $261.5 million / 42.6% | $220.5 million / 42.3% |
| Operating income / margin | $71.0 million / 11.6% | $57.6 million / 11.0% |
| Net income attributable to Novanta | $49.1 million | $60.1 million |
| Diluted EPS | $1.43 | $1.13 |
| Cash from operating activities | $89.6 million | $63.4 million |
- Revenue grew 17.8%. Acquisitions contributed $52.9 million, or 10.2% growth, and foreign exchange contributed $3.7 million, or 0.6%.
- Segment revenue growth was 7.3% in Photonics, 27.2% in Vision, and 24.8% in Precision Motion. Vision’s increase primarily reflected the first full year of WOM revenue; Precision Motion benefited from Zettlex and demand across product lines.
- Gross margin expanded 0.3 percentage points. Photonics margin increased to 47.0%, Vision declined to 37.4%, and Precision Motion rose to 45.0%.
- Net income attributable to Novanta fell despite higher operating income, principally because FY 2017 included a $26.4 million non-taxable gain when Novanta obtained control of Laser Quantum. EPS comparisons were also affected by redeemable noncontrolling-interest redemption-value adjustments: positive $1.8 million in 2018 versus negative $20.2 million in 2017.
- Q4 2018 revenue was $156.2 million versus $146.9 million in Q4 2017. Operating income was $15.7 million versus $19.1 million; net income attributable to Novanta was $11.6 million versus $8.9 million. Diluted EPS was $0.33 versus a reported rounded figure of $(0.00).
Cash, debt and liquidity
- Year-end cash was $82.0 million, down from $100.1 million. Operating cash flow was $89.6 million; capital expenditures were $14.7 million.
- Year-end principal debt was $209.6 million, comprising $74.5 million term debt and $135.1 million revolving borrowings. Balance-sheet debt carrying value was $207.4 million, net of debt issuance costs. The revolving facility had $189.9 million of unused capacity; facilities mature in May 2021.
- At year-end, the consolidated leverage ratio was 1.66 against a maximum of 3.50, and fixed-charge coverage was 5.11 against a minimum of 1.50.
- Management said operating cash flow should meet operating and capital needs for at least the next 12 months. Expected 2019 capital expenditures were $14–$16 million. A new $25 million share repurchase authorization was approved in October 2018; no shares had been bought under it by year-end. No cash dividend was anticipated in the foreseeable future.
Outlook, material events and risks
- No quantified revenue or earnings guidance is provided. Management’s stated strategy is to grow profitably, expand medical-market exposure, invest in product development, and improve margins and operations.
- 2018 acquisitions included Zettlex for approximately $32.0 million and the remaining Laser Quantum interest for $45.1 million in cash and restricted stock. Zettlex contributed $8.3 million revenue and a $1.8 million pretax loss from its May 1 acquisition date; its result included $4.4 million of earn-out compensation expense.
- Restructuring and acquisition-related costs totaled $8.0 million in 2018. The company expected $2.0–$3.5 million of additional charges for its 2019 restructuring program over the following 12 months; its 2018 restructuring program was expected to conclude in Q3 2019.
- Key exposures include cyclical industrial demand and customer order timing; tariffs and international trade changes, particularly U.S.–China; foreign exchange and floating-rate debt; dependence on some limited- or single-source suppliers; acquisition integration; medical-device and data-privacy regulation; and potential impairment of substantial goodwill and intangible assets. The company reported no goodwill or indefinite-lived intangible impairment in 2018.
- Contractual obligations included $99.0 million of purchase commitments, $55.9 million of operating lease payments, and $10.1 million of capital lease payments. The U.K. pension plan was underfunded by $3.8 million; expected 2019 contributions were approximately $0.9 million. Ordinary-course legal claims were not considered likely to have a material adverse effect, though outcomes were not assured.
- PwC issued unqualified opinions on the financial statements and internal control over financial reporting. Management also concluded disclosure controls and internal financial controls were effective at year-end.
Investor verification priorities
- Separate organic growth from acquisition-driven growth and assess whether demand across the three segments is sustaining the 2018 expansion.
- Track Vision’s lower margin and Precision Motion’s acquisition-related earn-out costs, alongside restructuring charges and expected savings.
- Monitor debt repayment, variable-rate interest exposure, covenant headroom, and cash availability across foreign subsidiaries.
- Review tariff effects, supplier concentration, acquisition performance, and the assumptions supporting goodwill and intangible-asset valuations.
- Confirm the timing and amount of 2019 restructuring costs, capital spending, pension contributions, and any share repurchases.